-
Mashup Score: 0Adakveo - European Medicines Agency - 12 month(s) ago
Adakveo
Source: European Medicines AgencyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.Further studies are needed to identify obstacles and improve patients’ access to these drugs, researchers wrote.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
People with sickle cell disease seldom receive newer pain medications. https://t.co/2KblbaXEO4 @OhioStateMed @Novartis #HemOnc #OncAlert #MedEd #sicklecelldisease #crizanlizumab #voxelotor
-
-
Mashup Score: 0Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study - 2 year(s) ago
Abstract. Background: Vaso-occlusive crises (VOC) are the most common acute complication of sickle cell disease (SCD). Crizanlizumab, an anti-P-selectin monoclo
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Early Evaluation of the Use of #Crizanlizumab in #SickleCellDisease : A National Alliance of Sickle Cell Centers Study It’s anti-P-selectin monoclonal antibody, FDA-approved disease-modifying therapy for SCD patients aged ≥16 yrs to ⬇️ frequency of VOC https://t.co/bq7c25PBIP
-
-
Mashup Score: 14Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial - 2 year(s) ago
Visual Abstract
Categories: Expert Picks, Latest HeadlinesTweet-
Can #Crizanlizumab induce endogenous thrombolysis in #COVID19 patients? Find out in #JACCBTS: https://t.co/SdvprcE0VD #openaccess #research #BasicScience #TranslationalScience #MedTwitter https://t.co/PrjcmrNQCs
-
-
Mashup Score: 0Use of Crizanlizumab for Pain Crisis Associated With SCD - 3 year(s) ago
Key opinion leaders focus on the use of crizanlizumab for painful crisis frequency in sickle cell disease.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
"It’s a different type of medicine and a different type of patient. It’s directed against #pain." - Patrick McGann, MD, MS (@PTMcGann), of @CincyChildrens #crizanlizumab #sicklecell https://t.co/S2DeUJv03l https://t.co/Wo9lxs8tfM
-
-
Mashup Score: 0
Wally Smith, MD, Virginia Commonwealth University, Richmond, VA, outlines the findings of a post hoc analysis of length of opioid…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASH20: Wally Smith of @VCUHealth presented results from the #Sustain trial Watch his interview w/ @VJHemOnc to hear more about the trial: 👉https://t.co/NNEMdwd4Av👈 @ASH_hematology @OncoAlert #OncoAlert #HemOnc #SickleCell #Crizanlizumab #CTsm #TrialUpdate
-
-
Mashup Score: 12FDA Approves Adakveo for Painful Complication of Sickle Cell Disease | CheckRare.com - 5 year(s) ago
The U.S. Food and Drug Administration (FDA) approved Adakveo (crizanlizumab-tmca) to reduce the frequency of pain crises in individuals with sickle cell disease. Adakveo (Novartis) is indicated for patients ages 16 or older is a humanized anti-P-selectin monoclonal antibody administered via monthly infusion. It binds to P-selectin on the surface of platelets and endothelium in …
Source: CheckRare.comCategories: Latest Headlines, Rare DiseaseTweet-
The U.S. Food and Drug Administration approved Adakveo #crizanlizumab-tmca to reduce the frequency of pain crises in individuals with sickle cell disease. @US_FDA @Novartis @SickleCellUK Novartis Sickle Cell Disease Awareness https://t.co/OqXSOY04kL
-
Noticia triste para las personas con #drepanocitosis. El comité asesor de la EMA recomienda, en base a los resultados del estudio fase 3, revocar la autorización a #crizanlizumab, el anti P-selectina aprobado condicionalmente con los resultados del fase 2 https://t.co/Ft4sgy2EuZ